SavedAdd your journal

Journals / Tüberküloz ve Toraks / 2014 / Cilt: 62 - Sayı: 4

Venous thromboembolism and cancer

Venöz tromboembolizm ve kanser

Oğuzhan OKUTAN
Ömer AYTEN
Pages
301–315
Publication Date
2022-11-04
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It has been aimed todescribe pathogenesis, risk factors and treatment approaches taking into account international consensus reports in this review.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Venous thromboembolism (VTE) is one of the complications which have significant influence on mortality in patient with cancer.Early mortality rate is high in cancer patients who have VTE.
📊
Key Findings & Data:VTE prophylaxis and/or treatment intreatment and follow-up of cancer patients will provide a reduction in mortality and morbidity rates.
💡
Conclusion & Impact:It has been aimed todescribe pathogenesis, risk factors and treatment approaches taking into account international consensus reports in this review.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Venous thromboembolism (VTE) is one of the complications which have significant influence on mortality in patient with cancer.Early mortality rate is high in cancer patients who have VTE. This complication is related with cell type and stage of the cancer,surgery applied during cancer treatment, applying catheter and the chemotherapeutic agents. VTE prophylaxis and/or treatment intreatment and follow-up of cancer patients will provide a reduction in mortality and morbidity rates. VTE prophylaxis and treatmentposes differences according to both treatment approaches which will be applied and the type of cancer. It has been aimed todescribe pathogenesis, risk factors and treatment approaches taking into account international consensus reports in this review.

Özet

Venöz tromboemboli (VTE) kanser hastalarında mortalite ve morbidite üzerinde önemli etkileri olan komplikasyonlardan birisidir. VTEgelişen kanser hastalarında erken mortalite geliş me oran ı daha yüksektir. Bu komplikasyon kanserin hücre tipi ve evresi, tedavi esna-sında uygulanan kanser cerrahisi, kateter uygulaması, kemoterapötik ajanlarla ilişkilidir. Kanser hastaların ın tedavi ve takiplerinde VTEprofilaksisi ve/veya tedavisi mortalite ve morbidite oranlarında azalmayı sa ğlayacaktır. VTE profilaksisi ve tedavisi, hastaların gerekkanser tipi, gerekse uygulanacak tedavi yakla şımlarına göre farklılıklar arz etmektedir. Bu derlemede uluslararas ı uzla şı raporları dik-kate alınarak patogenez, risk faktörleri ve tedavi yakla şımların ın anlatılması hedeflenmiştir.

🔖

Cite This Article

OKUTAN, O., AYTEN, Ö. (2022). Venous thromboembolism and cancer. Tüberküloz ve Toraks, Cilt: 62 - Sayı: 4, 301–315. https://ajindex.com/articles/618584

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R, et al. Rates of initial and recurrent thromboem- bolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999;78(5):285-91
  2. Trousseau A. Phlegmasia alba dolens. Clin Med Hotel-Dieu Paris 1865;3:654-712
  3. Agnelli G, Verso M, Management of venous thromboembo- lism in patients with cancer. J Throm Haemost 2011;9(Suppl 1):316-24
  4. Shinagare AB, Guo M, Hatabu H, Krajewski KM, Andriole K, Van den Abbeele AD, et al. Incidence of pulmonary embolism in oncologic outpatients at a tertiary cancer center. Cancer 2011;117(16):3860-6
  5. Johnson MJ, Sproule MW, Paul J. The prevalence and asso- ciated variables of deep venous thrombosis in patients with advanced cancer. Clin Oncol (R Coll Radiol) 1999;11(2):105-10
  6. Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006;166(4):458-64
  7. Jones A, Stockton DL, Simpson AJ, Murchison JT. Idiopathic venous thromboembolic disease is associated with a poor- er prognosis from subsequent malignancy. Br J Cancer 2009;101:840
  8. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombo- sis. JAMA 2005;293(6):715-22
  9. Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboem- bolism in a prospective observational study. Cancer 2005;104(12):2822-9
  10. Perry JR, Julian JA, Laperriere NJ, Geerts W, Agnelli G, Rogers LR, et al. PRODIGE: a randomized placebo-con- trolled trial of dalteparin low molecular weight heparin (LMWH) thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost 2010;8(9):1959-65
  11. Srkalovic G, Cameron MG, Rybicki L, Deitcher SR, KAttke- MArchant K, Hussein MA. Monoclonal gammopathy of undetermined significance and multiple myeloma are asso- ciated with an increased incidence of venothromboem- bolic disease. Cancer 2004;101(3):558-66
  12. Otten HM, Mathijssen J, ten Cate H, Soesan M, Inghels M, Richel DJ, et al. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy, an underesti- mated phenomenon. Arch Intern Med 2004;164:190-4
  13. Cheruku R, Tapazoglou E, Ensley J, Kish JA, Cummings GD, al-Sarraf M. The incidence and significance of thromboem- bolic complications in patients with hig